learn Tofacitinib
a JAK inhibitor for alopecia areata and other autoimmune conditions
- What is tofacitinib, and why is it discussed in relation to autoimmune-related hair loss such as alopecia areata? Tofacitinib is a prescription JAK inhibitor approved for rheumatoid arthritis, psoriatic arthritis and ulcerative colitis — not for alopecia areata. It is discussed for hair loss because a 2014 case report and a 2016 open-label trial reported regrowth in severe alopecia areata, but that use is off-label, the regrowth relapsed after stopping, and the drug carries an FDA boxed warning.
- Why is tofacitinib considered a medical treatment rather than a cosmetic or preventative hair product? Tofacitinib is a medical treatment because it targets underlying immune conditions affecting hair growth.
- What types of hair loss conditions are most commonly associated with tofacitinib use in clinical settings? Published studies link tofacitinib mainly to alopecia areata and its severe variants — as an off-label drug being studied for them, not as a cause of hair loss. The evidence is mostly small, open-label or retrospective, and relapse after stopping is commonly reported.
- All 5 questions on Tofacitinib →